A peptide that targets the energy-producing part of your cells (mitochondria) to help them work more efficiently.
Mitochondrial dysfunction, age-related energy decline, and certain heart conditions.
Strong animal data, but its large human heart-failure trial didn't meet its main goal.
What it is
SS-31 is a small peptide engineered to travel directly into the inner membrane of your mitochondria — the structures inside your cells responsible for producing energy. Once there, it binds to a molecule called cardiolipin, which is critical for keeping the mitochondria's energy-production machinery running efficiently. When cardiolipin gets damaged or disorganized, the electron transport chain — the process that actually makes ATP, your cells' energy currency — loses efficiency and produces more free radicals as a byproduct. SS-31 helps stabilize that structure. It was studied by a biotech company called Stealth BioTherapeutics for heart failure with preserved ejection fraction (a type where the heart pumps normally but doesn't relax properly) and for Barth syndrome, a rare genetic condition. The heart failure trial did not meet its primary goal, which is important context. The Barth syndrome data was more encouraging, and it holds FDA Orphan Drug Designation for that condition.
Potential benefits
Mitochondrial Function — Core Mechanism
Improves mitochondrial membrane potential, reduces mitochondrial free radical production, increases ATP output. Demonstrated across multiple disease models in animals. Mechanism well-characterized.
Cardiac Function
Phase 2 data in HFpEF showed improvements in 6-minute walk distance and QoL. Phase 3 did not meet primary endpoint. Positive Barth syndrome Phase 2 data.
Exercise Tolerance & Muscle Function
Aged animal and some Phase 2 human data show improved exercise capacity and skeletal muscle function — consistent with improved mitochondrial efficiency.
Kidney & Neuro Protection
Animal models show kidney and CNS protective effects. Human clinical data for these applications does not exist.
Risks and contraindications
Side Effects (from clinical trials)
- Injection site reactions — most common adverse event
- Fatigue · Headache
- Generally favorable short-term safety — no major organ toxicity at trial doses
Theoretical Risks
- Long-term mitochondrial adaptation effects unknown
- Mitochondrial metabolism altered in cancer cells — net effect unknown
- Interaction with cardiac meds, CoQ10, NAD+ precursors not characterized
Contraindications / cautions
- Active cancer · Pregnancy · Breastfeeding · Under 18
- Heart failure on complex cardiac medications — discuss with cardiologist
- Mitochondrial disease — direct pathway involvement
Research reality
Exceptionally strong and independently replicated. Multiple research groups have confirmed mitochondrial protective effects across a wide range of disease models. Among the most robust preclinical foundations of any compound in this guide.
Two rounds of human trials were completed. The earlier trial showed improvements in exercise capacity and quality of life. The larger, more definitive heart failure trial did not meet its primary goal — a significant result that deserves honest acknowledgment. The Barth syndrome Phase 2 results were more positive.
Long-term safety data doesn't exist. The short-term trial profile was favorable with no major organ toxicity. The Phase 3 failure doesn't eliminate biological interest in the compound, but it should recalibrate expectations built mainly on animal data.
Scientifically credible mechanism, strong independent animal data. The Phase 3 HFpEF trial failure is important context that deserves honest acknowledgment. For mitochondrial dysfunction, aging-related energy decline, and Barth syndrome, this remains a biologically credible option — with expectations calibrated to the clinical trial outcomes.